Seite wählen
LentiBOOST® is a highly effective, non-cytotoxic transduction enhancer for preclinical and clinical application of lentiviral vectors. It is a universal polaxamer-based, receptor-independent adjuvant which facilitates fusion of lenitivrus particles with cell membrane, significantly increasing transduction efficiency. LentiBOOST® can be applied to a wide range of clinically relevant cell types including CD34+ hematopoietic stem cells (HSCs), primary T cells, NK cells, fibroblasts, and hard-to-transduce murine T cells. These unique features make it a promising candidate to improve clinical transduction protocols for ex vivo gene therapies and CAR-T cell therapies. In the demonstration above, LentiBOOST™ increases transduction by a factor of 5.

LentiBOOST™ Pharma grade

For use in preclinical research and process development only. For quotes and further requests on this technology, please inquire with lentiboost@sirion-biotech.com.

LentiBOOST™ GMP grade

For use in clinical stage protocols. Currently included in more than 20  Phase III and I/II clinical trials in the US and in Europe. Licensing options for Clinical/Commercial Use and Development are available. Please inquire with licensing@sirion-biotech.com.

Benefits for Drug Development at a glance

Improved lentiviral transduction efficiency, up to 90%. ⇒ Increased expression levels of therapeutic protein have a favorable effect on success rates of clinical trials. Positive impact on cell proliferation for CD34+ and T cells. ⇒ Reduced cost of goods, optimized and stable transgenic cell manufacturing. Titratable vector copy numbers per cell. ⇒ Strong and durable therapeutic protein expression, in line with FDA/EMA criteria for ATMPs production. Successful track record of integration into clinical trials (III and I/II) in the US and Europe. ⇒ Proven lack of cell toxicity and prior clinical applications expedite IND filing. GMP grade batches available. ⇒ With all necessary documentation for direct integration into clinical programs. Read about LentiBOOST™ in the news. Contact us to discover how this adjuvant can excel your program: lentiboost@sirion-biotech.com.